Vericel Corp
Research Vericel Corp (VCEL) on Bullrun: market cap USD 2.21B, P/E 93.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVCEL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.21B
- P/E93.5
- Financial periodQ2 2026
- RevenueUSD 77.46M
- Net incomeUSD 2.21M
- Free cash flowUSD 14.26M
- Gross margin72.8%
Valuation Snapshot
latest market cap is USD 2.21B; P/E is 93.5.
Peer valuation comparison
Latest P/E is 93.49x versus a Healthcare sector median of 24.46x (282.2% above).
Latest P/E is 93.49x versus a United States median of 24.87x (276.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 276.26M | USD 16.52M | USD 24.75M | 74.4% | 0.32 | USD 100.09M | USD 96.37M | USD 354.64M |
| FY2024 | USD 237.22M | USD 10.36M | -USD 5.81M | 72.6% | 0.2 | USD 74.52M | USD 98.97M | USD 291.97M |
| FY2023 | USD 197.52M | -USD 3.18M | USD 15.30M | 68.6% | -0.07 | USD 69.09M | USD 88.04M | USD 225.95M |
| FY2022 | USD 163.70M | -USD 16.71M | USD 10.09M | 67.1% | -0.35 | USD 51.07M | USD 48.12M | USD 192.27M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.21B | 93.5 | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.82B | 116.2 | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.73B | 305.1 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.70B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.24B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.84B | n/a | n/a | n/a |
About Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vericel Corp's market cap?
Vericel Corp's market capitalization is USD 2.21B.
What is Vericel Corp's P/E ratio?
Vericel Corp's price-to-earnings (P/E) ratio is 93.5.
What does Vericel Corp do?
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.